Trial Profile
A Phase IIIB, Multicenter, Randomized, Double-Masked, Parallel-Group, Active-Controlled Study of the Safety and Efficacy of Difluprednate Ophthalmic Emulsion, 0.05% (Durezol) 4 Times Daily (QID) and Prednisolone Acetate Ophthalmic Suspension, 1.0% (Pred Forte) QID for the Treatment of Inflammation Following Cataract Surgery in Children 0 to 3 Years of Age
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Dec 2014
Price :
$35
*
At a glance
- Drugs Difluprednate (Primary) ; Prednisolone acetate
- Indications Postoperative inflammation
- Focus Therapeutic Use
- Sponsors Alcon
- 23 Dec 2014 New trial record